really pleased the cork far from being a conventional as the p t o found the prior art taught away from the claimed laboratory methods in this case the district court ignored that and its ruling should be reversed for two reasons sounds like one and three well there's certainly overlap church work as i think a number of judges of this court have noted between alice step two and one of the three analysis and in this case the district  critically these are laboratory method claims they do not include a diagnosis or prognosis element like the claims in the ohio case and like claim me example twenty nine claim two of the p t o guidelines don't believe that the district court gave the guidelines or the pre chosen protection of the guidelines skidmore deference and that's particularly relevant with respect to step two of alice because the p t o carefully analyzed the guidelines the prior art and held that these claims were innovative were certainly not conventional or routine and the district court virtually entirely ignored that in its opinion the only time it even mentions the prior is a summary footnote saying that it didn't think the prior art found these things in evade it never analyzed what the p t o had said it never went through the skidmore analysis of determining how persuasive the just the analysis was why it should or shouldn't be relied upon and how it applied in this case it least it step to judge laurie the district court didn't do what it was supposed to do under skidmore and given that the guidelines are entitled to skidmore conference if we believe that is a reversible error in and of itself there were plainly material issues of fact about whether this these laboratory methods used for this purpose were were conventional or routine and not in a book written fifty six you say the forty nine you say whether the detected m p o will be elevated pans on the techniques used to detect it even when using the prior art diagnostic test do you agree that m p o levels are in fact elevated in of ways and in most ways you look at it you're going to find m p o in the blood lower in patients who are having cardiovascular disease or heart of ask for events when you use this technique but  not necessarily this technique simply gives information that a physician or an ultimate diagnostician can use to try to make treatment plans it's not one hundred percent it's very different from what the d n a cases like aereo where it's either there or it isn't here in some patients m p o never gets elevated no matter what their risk of cardiovascular diseases it's definitely not an all or nothing thing here and all this is doing and i acknowledge this is not a method of treatment plan like the vanda case but it's similar because this is not an all or nothing proposition and what these laboratory patents do unlike the ohio patents which have a diagnosis element these simply give physicians the information they need a while with a whole lot of other information about an individual pat a patient whether to prescribe diet and exercise medication invasive procedures and helps you getting a leg from the laboratory techniques of the previous one saying this provid the process so so a lot of it's in the specification now we're in the claim in the claim it's the combination of the elements and the combination of the elements when you look at even the detecting the any body and contacting it when you look at the specification it talks about the way the allies which this relates to was done at page seven hundred fifty one of the appendix for example there are statements in the provisional application  established in the record is because there was no factual development but it explains that in the provisional application there's more statements about that in the specification i'm sorry what's the language in the claim that you either zero six for the five nine seven that you work claiming is this innovative aspect because this seems on all fours for me with whether it's area may you know i need this is just a diagnostic kit i don't see anything different and your spec itself says you're using standard prior art methods to do these things so i i'm so for example you don't see anything tell tell me precisely which in the claim and why that is really pointing to something that is already apart from the plasma sample that also caught away from by the prior art and then you have the control methodology to control against the general population or currently healthy subjects and the spec explains that fact control methodology and example one of the of the specification is done through this with iraq where is the control methodology and claim one i don't see that it's in claim one be it talks about as compared to a control m p o mass level and that why aren't you just detecting whether something to elevate it by comparing it to a control what am i missing i mean there's no you just chosen a control level and you are comparing it to sample you have to decide if it's more higher than the control you but the control methodology is explained in detail in the specification and the way it has to be done to be affective is to actually use a very significant number of samples with this particular lab methodology to control it can create the control curve it's not something that exists out there it's not a preprinted reference it's not a standard reference and it varies through time as you get more and more samples the control methodology changes and example one in the  so so just there each of the different elements you know made in isolation be conventional a combination and using it for this purpose was distinctly taught away from by the prior art and so in that case it's not routine in conventional and explaining a judge more understanding each of these elements how they fit together and wouldn't ordinarily skilled artisan would understand is why factual development was necessary that maybe this is a case that could have been disposed of in summary judgment after there was expert testimony and there was a full record that was developed but this was done at the pleading stage and it was done because the district court misinterpreted this court's decision of the ohio case as resolving any and all issues but these are lab method claims they are different as the court in the ohio case specifically said that lab method claims may be treated differently from diagnosis and prognosis claims the p t o guidelines do the same thing an example twenty nine they treat claim one of claim to very diagnosis element here what with i mean i fail to appreciate the difference between detecting in diagnosing i don't you're detecting an elevated m p o mass because you found that correlates to something important you are detecting  that's the way the claims are drafted for diagnosing pregnancy in a woman elevated level of a particular hormone why isn't that exactly on all fours with the sure you're not technically diagnosing pregnancy in fact claims and say that the claim say diagnosing an elevated level of i don't the level is so the physician can decide the treatment it's fundamentally different and i really urge the court if you look at it example twenty nine in the p t o guidelines the differences between claim one and claim to make this very clear if it doesn't have the diagnosis or prognosis elements it's not directed to a patent ineligible subject i want to i want to get a quick housekeeping question yeah true health argues that c c f never proposed a identify as needing construction and where in record right we identified a number of turns as needed in construction and in pages thirty five and thirty six of our blue brief and i believe in the footnote there we explain some of the terms that do ok and they were also raised to the trial court in the briefs in the trial court and the point there was we never got to claim construction so we didn't propose an elaborate construction of the claims you said these claims were acquired construction in the and whether the claim constructions race there were claims cited in broad statements made the claim to structure which required no different than the first the people in this case and in this court's decision in the first appeal it was made very clear that that simply invok we held similar guidelines were persuasive authority yet this court has treated the guidelines by providing notice and reviewing the examples making the determination in some instances that the examples are analogous in some instances on to explain why it disagreed with the analogy the district court rightly found an example one example twenty nine claims one was inapt that queen was directed to simply detecting a protein in a sample now these claims there was an attempt to draft the claims here in light of the first case given clinic one on example one but they couldn't get there because of the specification there are issues that there were techniques already available and used in the in the blood of patients having atherosclerotic cardiovascular disease their attempts to observe where they are claims to observe the natural law whether they're nominally drafted as laboratory methods which we define disagree with laboratory methods as we conventional wisdom taught away from the discovery but that the discovery of the natural law is that elevated m p o levels in the bloodstream free circulating in the bloodstream correlate the c b d there's been some discussion here about the prior art teaching a way see the correlation well look they did was they started with certain bodily samples and in tests if your interest process they are right that if we focus on free circulating in p would blood and we measure mass relativity that's the correlation that's the correlation that's that's where you see the correlation that's the same iterative process that's involved trial and error or any scientific discovery it's the same arguments that were rejected in myriad where the patent he's attempted to argue in the iterative scientific discovery process into the claims when it's not part of the analysis so correct me if i'm wrong but what you're saying is it's always elevated in persons with cardiovascular disease just wasn't determine basic laboratory technique you're detecting a protein in a bottle sample that's where it begins that's where it ends those types of claims are directed to the underlying assaye they may be sufficiently inventive to pass practitioners can't predict or determine if a patient cardiovascular disease is elevated levels so these are the basic antecedent steps that are necessary to observe the natural law and this court has routinely stated that claims which merely recite observed or state natural law without an application are fail to satisfy the want to one test that's what we have here if the claims were limited to detecting m p o in the blood they may be analogous to to the example captured by the presumption of liberty under section two eighty two and again the district court treated the guidelines as this court has treated the guidelines gave them notice analyzed the p t o s interpretation a at eleven fifty three that these are these are a lost lives they are generally examples that they are specific to the facts of those examples and that other claims need to be interpreted independently and that's what happened here think that there are serious questions or there are questions about how much difference to give the guidelines given that the case law is being developed by the supreme court and this court the most recent guidelines published by the p t o which i believe came out this week  made very clear that the guidelines are p q interpretations of supreme court and federal circuit precedent they're following the case law developments so i think that puts the guidelines in sort of a great area how much effort should be afforded them given that ultimately this is a creative doctrine and the courts are interpreted how to apply want to whine but nonetheless in this in this case the court went through the necessary process of taking notice of the guidelines analyzing the you can figure out that it is possible that it could be eligible method of detecting this protein which didn't wasn't known before and thus we aren't sure how you could detect it so it's the method of detecting that protein because the protein was unknown and there are ask you whether you agree with that is that a possibly a basis for distinguishing even if the p t o is right about example twenty nine for example is that a potential basis for distinguishing this case for eligibility purposes from  art or advancement of what was done previously was this discovery and now we're reciting the lab method that kicking all of that into consideration claim one itself could be problematic under other facts here as interpreted it's simply measuring jail in the bloodstream pretty close to what we have here i mean then you're using that the detection to observe the natural law the natural law is the focus of the claim that the underlying laboratory technique it's we want to observe the natural the necessary steps we need to get there and at that point they're focused on the natural law and there has to be some application some integration of the natural law into a method of producing things or into a method of treat all the potential types of claims that might have been drafted once the inventors discover the natural correlation here the natural law but they stop at here are the antecedent steps that need to be taking just to observe it and then you stop the product of the claims is merely observing the natural law and so when we get to step to the just record accepted the argument that this was the first time these well known techniques have been applied to this natural law but at step two the natural law has to be divorced from you know six has to be treated as part of the prior art and that argument was rejected by this court burial so it was rejected by this court in genetic technology so you disagree with parent patent and used here in its prior decision that the sampling techniques the statistical techniques used were conventional and to the extent their arguments being made about a study needs to be sufficiently power rosenberg a few brief points first of all in response to judge moore's question i think the question about whether the protein is new conflates the step one and step two analysis of alice what the p t o is saying in the guidelines is this  directed at step one to a natural phenomenon and if it's a lab method to detect a protein it's not whether the proteins new or novel is a step to analysis and that's step two here i want to emphasize the prior or absolutely away from this method of analysis it's oil away from using these lab methods it's what away from measuring m p o in blood plasma as being medically significant and that is just crap and the district court in fire really ignored that that leads us into the skidmore point i agree judge laurie that example twenty nine is critical here both with step one and step two and while my opponent is right that the district court did discuss a little bit the guidelines with respect to step one there was no discussion of what the p t o did with the guidelines or the prior are at step two none in the district court's decision that's reversible error third when you actually look at the state of the or i want to emphasize the specification and if there were factual development the facts would have shown that there were years and years of research by the leaders in the field in m p o research before they ever got to be as method as they try to m p s five for years they looked at the prior art references that have looked at blood plasma and found that m p o could not be measured in any way that was significant i would emphasize to the court i'm not aware of any life sciences case where this court has upheld a section one hundred one dismissal in the pleadings where the prior ar tore away from claims laboratory methods and finally i would just like to mention the p t o guidelines that were issued this week for notice and comment reaffirm their view that their prior analysis in the life sciences area is valid